Peter M. Voorhees, MD, shares key insights from the 2025 American Society of Clinical Oncology Annual Meeting, specifically in the multiple myeloma space.

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Researchers sought to determine whether adding elotuzumab to PVd would be safe and effective in treating patients with relapsed or refractory MM.

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Bristol-Myers Squibb, in partnership with K36 Therapeutics, updated progress on their Phase 1 trial of KTX-1001 for relapsed ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

In a move that signals intensifying ambitions in the cancer therapeutics arena, pharmaceutical titan AbbVie Inc. unveiled Thursday a blockbuster $2 billion exclusive licensing agreement with Swiss ...

IGI Therapeutics SA, has signed with Abbvie Inc. a global licensing partnership for trispecific antibody ISB-2001 worth $1.925 billion plus royalties. ISB-2001, which targets BCMA, CD38 and CD3, is in ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...